Skip to main content

Table 3 Multigene predictors of response to endocrine treatment

From: Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction

Authors

Signature

Number of casesa

Treatment

Context

Method

Platform

Jansen et al. [110]

44 genes

48 training set, 66 validation set

TAM

Recurrent breast cancer

Top-down (response vs. progression)

Microarray (local)

Loi et al. [112]

Tamoxifen predictor (181 genes)

99 training set, 69 validation set

87 validation set

TAM

Adjuvant treatment

Top-down (relapse vs. no relapse)

Microarray (Affymetrix, Santa Clara, CA, USA)

Oh et al. [111]

Estrogen-regulated genes (822 genes)

Cell lines + 65 discovery set, 60 validation set (1)

Heterogeneous TAM (1)

Adjuvant treatment

Bottom-up (estrogen induced gene expression changes in MCF-7 cell lines)

Microarray (Agilent Technologies, Inc., Santa Clara, CA, USA)

  

90 validation set (2)

TAM +/- NAC (2)

   
  

250 validation set (3)

Heterogeneous (3)

   

Symmans et al. [113]

SET index (165 genes)

437 training set, 225 + 298 validation set (1)

Heterogeneous TAM (1)

Adjuvant treatment

Bottom-up (genes coexpressed with estrogen receptor)

Microarray (Affymetrix)

  

122 validation set (2)

NAC + TAM or Al (2)

   
  

208 + 133 validation set (3)

Non-treated (3)

   
  1. aNumber of cases in training and validation sets. AI, aromatase inhibitor; NAC, neoadjuvant chemotherapy; SET, sensitivity to endocrine therapy; TAM, tamoxifen.